IPO registrations (S-1, F-1) · Registrants
Fresh Tracks Therapeutics, Inc.
- SEC CIK
- 819050 · filings on EDGAR ↗
- Former names
- Brickell Biotech, Inc. (2019–2022); VICAL INC (1995–2019); VICAL, INC. (1994–1994)
- Registration
- Form S-1, first filed 2017-10-16, last 2023-12-19; 5 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2017-11-09; declared effective 2017-11-07; withdrawal requested 2023-12-20
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 2000 CENTRAL AVENUE, SUITE 100, Boulder, CO 80301
- EIN
- 93-0948554
- EDGAR entity type
- operating
- Insiders and CEO pay
- Fresh Tracks Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $1.75 per share (424B4 filed 2017-11-09)
- Shares sold
- 7,051,429
- Gross proceeds
- $12,340,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol VICL
- Lead underwriters
- H.C. Wainwright
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: FRESH TRACKS THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: FRESH TRACKS THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Brickell Biotech, Inc. EXACT (CIK (EXACT))
- SEC filer: Brickell Biotech, Inc. EXACT (CIK (EXACT))
- Person page: George B Abercrombie Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 36
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-10-16 | S-1 | S-1 (registration) | VICAL INC | 0000950123-17-009078 ↗ |
| 2017-10-30 | S-1/A | S-1/A (amendment) | VICAL INC | 0000950123-17-009344 ↗ |
| 2017-11-07 | S-1/A | S-1/A (amendment) | VICAL INC | 0000950123-17-009602 ↗ |
| 2017-11-07 | EFFECT | EFFECT (declared effective) | VICAL INC | 9999999995-17-002902 ↗ |
| 2017-11-08 | S-1MEF | S-1MEF (added securities) | VICAL INC | 0001193125-17-336398 ↗ |
| 2017-11-09 | 424B4 | 424B4 (final prospectus) | VICAL INC | 0001564590-17-023292 ↗ |
| 2018-06-11 | EFFECT | EFFECT (declared effective) | VICAL INC | 9999999995-18-001481 ↗ |
| 2020-03-19 | EFFECT | EFFECT (declared effective) | Brickell Biotech, Inc. | 9999999995-20-000595 ↗ |
| 2020-04-03 | S-1 | S-1 (registration) | Brickell Biotech, Inc. | 0000819050-20-000059 ↗ |
| 2020-04-13 | EFFECT | EFFECT (declared effective) | Brickell Biotech, Inc. | 9999999995-20-000731 ↗ |
| 2020-04-24 | S-1/A | S-1/A (amendment) | Brickell Biotech, Inc. | 0000819050-20-000098 ↗ |
| 2020-04-28 | EFFECT | EFFECT (declared effective) | Brickell Biotech, Inc. | 9999999995-20-000901 ↗ |
| 2020-05-15 | S-1 | S-1 (registration) | Brickell Biotech, Inc. | 0000819050-20-000119 ↗ |
| 2020-06-08 | S-1/A | S-1/A (amendment) | Brickell Biotech, Inc. | 0000819050-20-000127 ↗ |
| 2020-06-17 | S-1/A | S-1/A (amendment) | Brickell Biotech, Inc. | 0000819050-20-000146 ↗ |
| 2020-06-17 | S-1MEF | S-1MEF (added securities) | Brickell Biotech, Inc. | 0000819050-20-000153 ↗ |
| 2020-06-17 | EFFECT | EFFECT (declared effective) | Brickell Biotech, Inc. | 9999999995-20-001460 ↗ |
| 2020-06-18 | 424B4 | 424B4 (final prospectus) | Brickell Biotech, Inc. | 0000819050-20-000158 ↗ |
| 2020-10-13 | S-1 | S-1 (registration) | Brickell Biotech, Inc. | 0000819050-20-000205 ↗ |
| 2020-10-19 | S-1/A | S-1/A (amendment) | Brickell Biotech, Inc. | 0000819050-20-000208 ↗ |
| 2020-10-22 | S-1/A | S-1/A (amendment) | Brickell Biotech, Inc. | 0000819050-20-000216 ↗ |
| 2020-10-22 | EFFECT | EFFECT (declared effective) | Brickell Biotech, Inc. | 9999999995-20-002957 ↗ |
| 2020-10-23 | 424B4 | 424B4 (final prospectus) | Brickell Biotech, Inc. | 0000819050-20-000223 ↗ |
| 2021-03-17 | EFFECT | EFFECT (declared effective) | Brickell Biotech, Inc. | 9999999995-21-000984 ↗ |
| 2022-09-02 | S-1 | S-1 (registration) | Brickell Biotech, Inc. | 0000819050-22-000145 ↗ |
| 2022-09-09 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-22-002657 ↗ |
| 2023-12-19 | S-1/A | S-1/A (amendment) | Fresh Tracks Therapeutics, Inc. | 0001628280-23-041828 ↗ |
| 2023-12-20 | RW | RW (withdrawal request) | Fresh Tracks Therapeutics, Inc. | 0001628280-23-042300 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003701 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003702 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003703 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003704 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003705 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003706 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003707 ↗ |
| 2023-12-21 | EFFECT | EFFECT (declared effective) | Fresh Tracks Therapeutics, Inc. | 9999999995-23-003708 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-11-07 | S-1/A | registration statement | $12.06 | 10,000,000 | $120,600,000 | Nasdaq VICL | 1 | primary document; price line, shares headline, proceeds computed, cover names 1 | document ↗ | |
| 2017-11-09 | 424B4 | final prospectus | $1.75 | 7,051,429 | $12,340,000 | Nasdaq VICL | 1 | primary document; price sentence, shares headline, proceeds computed, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| SAMANT VIJAY B | Director; Director,Officer | President and CEO; President & CEO | 85 | 2006–2022 | |
| Broadfoot Jill Marie | Officer | Sr Vice President, CFO, Sec; Vice President, CFO, Secretary | 15 | 2006–2013 | |
| KASLOW DAVID C MD | Officer | Chief Scientific Officer | 3 | 2006 | |
| CAMPBELL ROBERT H | Director | 8 | 2006–2012 | ||
| DOUGLAS R GORDON | Director | 15 | 2006–2018 | ||
| LYONS GARY A | Director | 25 | 2006–2022 | ||
| MERTON ROBERT C | Director | 18 | 2006–2018 | ||
| ROLLAND ALAIN P PHD | Officer | EVP, Product Development; Exec VP, Product Development; Exec. VP, Product Development; Sr. VP, Product Development | 48 | 2006–2013 | |
| Fullerton Management Pte Ltd | TenPercentOwner | 7 | 2006–2009 | ||
| TEMASEK HOLDINGS (PRIVATE) LTD | TenPercentOwner | 7 | 2006–2009 | ||
| Temasek Life Sciences Private LTD | TenPercentOwner | 7 | 2006–2009 | ||
| V-Sciences Investments Pte Ltd | TenPercentOwner | 7 | 2006–2009 | ||
| MARXE AUSTIN W & GREENHOUSE DAVID M | TenPercentOwner | 3 | 2009 | ||
| SINGER JAMES R | TenPercentOwner | 13 | 2012–2013 | ||
| MORROW GEORGE J | Director | 8 | 2012–2018 | ||
| Ramos Anthony Alan | Officer | Chief Accounting Officer; VP, Chief Accounting Officer; VP, Chief Financial Officer | 29 | 2013–2018 | |
| Beleson Richard M | Director | 7 | 2013–2018 | ||
| SHERWIN STEPHEN A | Director | 4 | 2013–2015 | ||
| BILINSKY IGOR | Officer | Senior VP, Corporate Dev't; Sr VP, Corporate Development | 12 | 2013–2015 | |
| SMITH LAWRENCE RUSSELL | Officer | Sr VP, Research; VP, Vaccine Research | 24 | 2013–2018 | |
| SHENK THOMAS E | Director | 5 | 2015–2018 | ||
| AnGes MG, Inc. | TenPercentOwner | 1 | 2016 | ||
| Mammen Mammen | Officer | Sr VP, Clinical Development | 3 | 2017–2018 | |
| ARMISTICE CAPITAL, LLC | TenPercentOwner | 8 | 2018–2019 | ||
| Armistice Capital Master Fund Ltd. | TenPercentOwner | 8 | 2018–2019 | ||
| Boyd Steven | TenPercentOwner | 8 | 2018–2019 | ||
| ABERCROMBIE GEORGE B | Director; Director,Officer | CHIEF EXECUTIVE OFFICER | 3 | 2019–2020 | person page Fuzzy |
| Breton Jose | Officer | Chief Accounting Officer | 6 | 2019–2022 | |
| Brown Robert Busard | Director,Officer; Officer | Chief Executive Officer | 6 | 2019–2022 | |
| Carruthers R Michael | Officer | Chief Financial Officer | 2 | 2019–2020 | |
| Chadha Deepak | Officer | Chief R&D Officer and COO; Chief Research & Dev. Officer; Former Chief R&D Officer & COO | 10 | 2019–2023 | |
| HARDY REGINALD L | Director,Officer | Chairman of the Board; CHAIRMAN OF THE BOARD | 13 | 2019–2022 | |
| Ju William | Director | 1 | 2019 | ||
| Levy Adam Scott | Officer | Chief Business Officer | 2 | 2019–2020 | |
| McAvoy David R. | Officer | Gen Counsel, CCO, & Secretary; General Counsel; General Counsel and CCO | 12 | 2019–2023 | |
| Sklawer Andrew D | Officer | COO and Secretary; President; President and CEO | 10 | 2019–2023 | |
| VERU DENNISON T | Director | 10 | 2019–2022 | ||
| Ahuja Sanjeev | Officer | Chief Medical Officer | 2 | 2019 | |
| Marchio Albert N II | Director,Officer; Officer | CEO and CFO; Chief Financial Officer | 5 | 2020–2024 | |
| Luchi Monica E. | Officer | Chief Medical Officer | 3 | 2021–2022 | |
| Fox-Colis Aaron | Officer | VP of Finance & CAO | 4 | 2023–2024 | |
| Exploration Capital Fund, LP | TenPercentOwner | 2 | 2023 | ||
| Exploration Capital General Partner, LLC | TenPercentOwner | 2 | 2023 | ||
| Exploration Capital, LLC | TenPercentOwner | 20 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-06-07 | Brickell Biotech, Inc. | Pharmaceuticals | $10 | $10 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | FRESH TRACKS THERAPEUTICS, INC. | State business registries | EIN (EXACT, as the state registration reports it) | |
| Form 5500 plan sponsor | FRESH TRACKS THERAPEUTICS, INC. | EIN (EXACT) | ||
| Form D issuer | Brickell Biotech, Inc. | Form D private offerings | CIK (EXACT) | |
| Person page | George B Abercrombie | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) | |
| SEC filer | Brickell Biotech, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.